Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amantadine for fatigue in multiple sclerosis.

C Taus1, G Giuliani, E Pucci

  • 1Unità Operativa di neurologia, Ospedale San Salvatore, Piazzale Cinelli,4, Pesaro, Italy. cristianataus@yahoo.it

The Cochrane Database of Systematic Reviews
|June 14, 2003
PubMed
Summary

Amantadine is generally well-tolerated for Multiple Sclerosis (MS) fatigue, but evidence for its effectiveness is weak. More high-quality trials are needed to guide treatment decisions for MS-related fatigue.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of a New Riluzole-Based Compound VA945 on Sodium and Potassium Conductances Expressed by SH-SY5Y- Derived Neurons.

Journal of neurochemistry·2025
Same author

Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.

Journal of neurology·2025
Same author

Non-palpable breast lesions localization techniques - A new priority: Results of a Senonetwork survey among breast centers in Italy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2024
Same author

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal of medical economics·2023
Same author

Diagnosis concealment is prevalent in MS, and associated with diagnosis experience.

Multiple sclerosis and related disorders·2022
Same author

Impact of the COVID-19 pandemic on multidrug-resistant hospital-acquired bacterial infections.

The Journal of hospital infection·2022

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Fatigue is a primary disabling symptom in Multiple Sclerosis (MS), significantly impacting patient quality of life.
  • Current treatment recommendations for MS fatigue lack robust scientific evidence.
  • Amantadine is often cited as a first-line treatment despite limited supporting data.

Purpose of the Study:

  • To systematically review existing evidence on the effectiveness and safety of amantadine for reducing fatigue in individuals with MS.
  • To evaluate the quality of randomized controlled trials (RCTs) investigating amantadine for MS-related fatigue.

Main Methods:

  • Systematic review of RCTs identified through comprehensive database searches and manual review.
  • Inclusion criteria specified double-blind, placebo or active-controlled trials in MS patients with fatigue.

Related Experiment Videos

  • Data extraction and quality assessment performed by multiple reviewers, with attempts to obtain missing information.

    • Main Results:

    • Four trials involving 236 MS patients met inclusion criteria; study quality was poor and prone to bias.
    • Studies reported minor, inconsistent improvements in fatigue with amantadine, with undetermined clinical relevance.
    • Amantadine was well-tolerated, with side effect rates similar to placebo and low discontinuation rates.

    Conclusions:

    • Amantadine is well-tolerated but its efficacy for MS fatigue is poorly documented.
    • Insufficient evidence exists to support current prescribing recommendations for amantadine in MS fatigue.
    • Future research should focus on understanding MS fatigue mechanisms, standardizing outcome measures, and conducting high-quality RCTs.